Unlocking the molecular mechanisms of DNA repair and platinum drug resistance in cancer chemotherapy

Current Drug Therapy

Volumn 4, Issue 1, 2009, Pages 19-28

  Yu, Jing Jie ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylation; DNA repair; Epigenetic regulation; Genetic alteration; Methylation; Platinum resistance

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DNA DIRECTED DNA POLYMERASE BETA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HISTONE; IMATINIB; OXALIPLATIN; PLATINUM COMPLEX; PROTEIN P53; SORAFENIB; SUNITINIB; TRASTUZUMAB;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BLADDER CANCER; BONE CANCER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COLON TUMOR; DNA DAMAGE; DNA METHYLATION; DNA MODIFICATION; DNA REPAIR; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; EXCISION REPAIR; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC REGULATION; GENETIC VARIABILITY; HEAD AND NECK CANCER; HETEROZYGOTE; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MISMATCH REPAIR; MYELODYSPLASTIC SYNDROME; NERVOUS SYSTEM TUMOR; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVARY TUMOR; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; REPRESSOR GENE; REVIEW; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TESTIS CANCER; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

EID: 65349152572     PISSN: 15748855     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488509787081895     Document Type: Review

References (175)

1. Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM. The Role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 2008; 48: 495-535.
2. Kelland LR. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573-84.
3. Wernyj RP, Morin PJ. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat 2004; 7: 227-32.
4. Fojo T, Bates S. Strategies for reversing drug resistance. Oncogene 2003; 22: 7512-23.
5. Agarwal R, Kaye SB. Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3: 502-16.
6. Basik M, Stoler DL, Kontzoglou KC, Rodriguez-Bigas MA, Petrelli NJ, Anderson GR. Genomic instability in sporadic colorectal cancer quantitated by intersimple sequence repeat PCR analysis. Genes Chromosomes Cancer 1997; 18: 19-29.
7. Sood AK, Buller RE. Genomic instability in ovarian cancer: a reassessment using an arbitrarily primed polymerase chain reaction. Oncogene 1996; 13: 2499-504.
8. Cass I, Kholodilov N, Runowicz CD, Klinger HP. Microsatellite instability in ovarian carcinoma. Proc Am Assoc Cancer Res 1996; 37: 544.
9. Dhillon VS, Aslam M, Husain SA. The contribution of genetic and epigenetic changes in granulosa cell tumors of ovarian origin. Clin Cancer Res 2004; 10: 5537-45.
10. Das PM, Singal R. DNA Methylation and Cancer. J Clin Oncol 2004; 22: 4632-42.
11. Hadnagy A, Beaulieu R, Balicki D. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics. Mol Cancer Ther 2008; 7: 740-8.
12. Press JZ, Luca AD, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: (17doi:10.1186/1471-2407-8-17).
13. Renault B, Calistri D, Buonsanti G, Nanni O, Amadori D, Ranzani GN. Microsatellite instability and mutations of p53 and TGF-β RII genes in gastric cancer. Hum Genet 1996; 98: 601-7.
14. Skilling JS, Sood AK, Niemann T, Lager DJ, Buller RE. An abundance of p53 null mutations in ovarian carcinoma. Oncogene 1996; 13: 117-23.
15. Elsaleh H, Powell B, Soontrapornchai P, et al. p53 gene mutation, microsatellite instability, and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 2000; 58: 52-9.
16. Francia G, Green SK, Bocci G, et al. Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents. Mol Cancer Ther 2005; 4: 1484-94.
17. Lord RVN, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286-91.
18. Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB. p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 2001; 61: 1508-16.
19. Lin X, Howell SB. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther 2006; 5: 1239-47.
20. Mueller MD. Report on platinum drug symposium. West Virgin Med J 2008; 104: 8-9.
21. O'Dwyer PJ, Stevenson JP, Johnson SW. clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000; 59: 19-27.
22. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10: 706-17.
23. Esposito M, Fulco RA, Collecchi P, et al. Improved therapeutic index of cisplatin by procaine hydrochloride. J Natl Cancer Inst 1990; 82: 677-84.
24. Chu G, Chang E. Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc Natl Acad Sci 1990; 87: 3324-7.
25. Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991; 87: 772-7.
26. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T. Cisplatin resistance in human cancers. Pharm Ther 1991; 52: 385-406.
27. Johnson SW, Swiggard PA, Handel LM, et al. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res 1994; 54: 5911-6.
28. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003; 63: 1311-6.
29. Huang J-C, Zamble DB, Reardon JT, Lippard SJ, Sancar A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 1994; 91: 10394-8.
30. Yu JJ, Mueller MD. In: Bonetti A, Leone R, Muggia F, Howell SB. Eds. Platinum and other heavy metal compounds in cancer chemotherapy: Molecular mechanisms and clinical applications. New York, Humana press 2009; 189-94.
31. Yan QW, Reed E, Zhong XS, Thornton K, Guo Y, Yu JJ. MZF1 possesses a repressively regulatory function in ERCC1 expression. Biochim Pharmacol 2006; 71: 761-71.
32. Welsh C, Day R, McGurk C, Masters JRW, Wood RD, Köberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004; 110: 352-61.
33. Köberle B, Masters JRW, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999; 9: 273-8.
34. Köberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JRW. DNA Repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 1997; 70: 551-5.
35. Kelland LR, Mistry P, Abel G, et al. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res 1992; 52: 1710-6.
36. Olaussen KA, Mountzios G, Soria JC. ERCC1 as a risk stratifier in platinum-based chemotherapy for non-small-cell lung cancer. Curr Opin Pulm Med 2007; 13: 284-9.
37. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17: 1818-25.
38. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007; 25: 2747-54.
39. Shafee N, Smith CR, Wei S, et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 2008; 68: 3243-50.
40. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-8.
41. Kharbanda S, Saleem A, Data R, Yuan Z, Weichselbaum R, Kufe D. Ionizing radiation induces rapid tyrosine phosphorylation of p34(cdc2). Cancer Res 1994; 54: 1412-4.
42. Rotman G, Shiloh Y. Ataxia-telangiectasia: is ATM a sensor of oxidative damage and stress? BioEssays 1997; 19: 911-7.
43. Hoang J-M, Cottu PH, Benedicte T, Salmon RJ, Thomas G, Hamelin R. BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res 1997; 57: 300-3.
44. Zhou X-P, Hoang J-M, Li Y-J, et al. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer 1998; 21: 101-7.
45. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat Res 2005; 577: 275-83.
46. Weinert T. A DNA damage checkpoint meets the cell cycle engine. Science 1997; 277: 1450-1.
47. Zhou BBS, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433-9.
48. Chu G. Cellular responses to cisplatin: The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994; 269: 787-90.
49. Sancar A. Mechanisms of DNA excision repair. Science 1994; 266: 1954-6.
50. Wood RD. DNA repair in eukaryotes. Annu Rev Biochem 1996; 65: 135-67.
51. Seeberg E, Eide L, Bjørås M. The base excision repair pathway. Trends Biochem Sci 1995; 20: 391-7.
52. Lindahl T, Karran P, Wood RD. DNA excision repair pathways. Curr Opin Genet Dev 1997; 7: 158-69.
53. Kelley MR, Cheng L, Foster R, et al. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin Cancer Res 2001; 7: 824-30.
54. Fishel ML, Seo YR, Smith ML, Kelley MR. Imbalancing the DNA base excision repair pathway in the mitochondria; targeting and overexpressing N-methylpurine DNA glycosylase in mitochondria leads to enhanced cell killing. Cancer Res 2003; 63: 608-15.
55. Lindahl T. An N-glycosidase from Escherichia coli that releases free uracil from DNA containing deaminated cytosine residues. Proc Natl Acad Sci USA 1974; 71: 3649-53.
56. Olsen LC, Aasland R, Wittwer CU, Krokan HE, Helland DE. Molecular cloning of human uracil-DNA glycosylase, a highly conserved DNA repair enzyme. EMBO J 1989; 8: 3121-5.
57. Liu Y, Prasad R, Beard WA, et al. Coordination of steps in single-nucleotide base excision repair mediated by apurinic/ apyri-midinic endonuclease 1 and DNA polymerase beta. J Biol Chem 2007; 282: 13532-41.
58. Sukhanova MV, Khodyreva SN, Lebedeva NA, Prasad R, Wilson SH, Lavrik OI. Human base excision repair enzymes apurinic/apyrimidinic endonuclease1 (APE1), DNA polymerase β and poly(ADP-ribose) polymerase 1: interplay between strand-displacement DNA synthesis and proof reading exonuclease activity. Nucleic Acids Res 2005; 33: 1222-9.
59. Johnson A, O'Donnell M. Cellular DNA replicases: components and dynamics at the replication fork. Annu Rev Biochem 2005; 74: 283-315.
60. Huang J-C, Svoboda DL, Reardon JT, Sancar A. Human nucleotide excision nuclease removes thymine dimers from DNA by incising the 22nd phosphodiester bond 5′ and the 6th phosphodiester bond 3′ to the photodimer. Proc Natl Acad Sci USA 1992; 89: 3664-8.
61. Moggs JG, Yarema KJ, Essigmann JM, Wood RD. Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct. J Biol Chem 1996; 271: 7177-86.
62. Furuta T, Ueda T, Aune G, et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002; 62: 4899-902.
63. Wood RD. Nucleotide excision repair in mammalian cells. J Biol Chem 1997; 272: 23465-8.
64. Matsunaga T, Mu D, Park C-H, Reardon JT, Sancar A. Human DNA repair excision nuclease. Analysis of the roles of the subunits involved in dual incisions by using anti-XPG and anti-ERCC1 antibodies. J Biol Chem 1995; 270: 20862-9.
65. Hoeijmakers JHJ. Nucleotide excision repair I: from E. coli to yeast. Trends Genet 1993; 9: 173-7.
66. Hanawalt PC. Transcription-coupled repair and human disease. Science 1994; 266: 1957-8.
67. Lehmann AR. Nucleotide excision repair and the link with transcription. Trends Biochem Sci 1995; 20: 402-5.
68. Leadon SA, Lawrence DA. Strand-selective repair of DNA damage in the yeast GAL7 gene requires RNA polymerase II. J Biol Chem 1992; 267: 23175-82.
69. Weilbaecher RG, Awrey DE, Edwards AM, Kane CM. Intrinsic Transcript Cleavage in Yeast RNA Polymerase II Elongation Complexes. J Biol Chem 2003; 278: 24189-99.
70. Jung Y, Lippard SJ. RNA polymerase II blockage by cisplatin-damaged DNA: Stability and polyubiquitylation of stalled polymerase. J Biol Chem 2006; 281: 1361-70.
71. Nesser NK, Peterson DO, Hawley DK. RNA polymerase II subunit Rpb9 is important for transcriptional fidelity in vivo. Proc Natl Acad Sci 2006; 103: 3268-73.
72. Thoma BS, Wakasugi M, Christensen J, Reddy MC, Vasquez KM. Human XPC-hHR23B interacts with XPA-RPA in the recognition of triplex-directed psoralen DNA interstrand crosslinks. Nucleic Acids Res 2005; 33: 2993-3001.
73. Li J, Wang QE, Zhu Q, et al. DNA damage binding protein component DDB1 participates in nucleotide excision repair through DDB2 DNA-binding and cullin 4A ubiquitin ligase activity. Cancer Res 2006; 66: 8590-7.
74. Wakasugi M, Sancar A. Order of assembly of human DNA repair excision nuclease. J Biol Chem 1999; 274: 18759-68.
75. Reardon JT, Sancar A. Molecular anatomy of the human excision nuclease assembled at sites of DNA damage. Mol Cell Biol 2002; 22: 5938-45.
76. Chang IY, Kim MH, Kim HB, et al. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 2005; 327: 225-33.
77. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 2005; 11: 6100-2.
78. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19: 4298-304.
79. Reed E. ERCC1 measurements in clinical oncology. N Engl J Med 2006; 355: 1054-5.
80. Jackson SP, Jeggo PA. DNA double-strand break repair and V(D)J recombination: involvement of DNA-PK. Trends Biochem Sci 1995; 20: 412-5.
81. Finnie NJ, Gottlieb TM, Blunt T, Jeggo PA, Jackson SP. DNA-dependent protein kinase activity is absent in xrs-6 Cells: implications for site-specific recombination and DNA double-strand break repair. Proc Natl Acad Sci 1995; 92: 320-4.
82. Taccioli GE, Rathbun G, Oltz E, Stamato T, Jeqqo PA, Alt FW. Impairment of V(D)J recombination in double-strand break repair mutants. Science 1993; 260: 207-10.
83. Lindahl T, Satoh MS, Poirier GG, Klungland A. Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci 1995; 20: 405-11.
84. Despras E, Pfeiffer P, Salles B, et al. Long-term XPC silencing reduces DNA double-strand break repair. Cancer Res 2007; 67: 2526-34.
85. Selva EM, New L, Crouse GF, Lahue RS. Mismatch correction acts as a barrier to homeologous recombination in Saccharomyces cerevisiae. Genetics 1995; 139: 1175-88.
86. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999; 286: 1162-6.
87. Cousineau I, Abaji C, Belmaaza A. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis. Cancer Res 2005; 65: 11384-91.
88. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104: 2807-16.
89. Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene 2002; 21: 8981-93.
90. Xia F, Taghian DG, DeFrank JS, et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci 2001; 98: 8644-9.
91. Kuhfittig-Kulle S, Feldmann E, Odersky A, et al. The mutagenic potential of non-homologous end joining in the absence of the NHEJ core factors Ku70/80, DNA-PKcs and XRCC4-LigIV. Mutagenesis 2007; 22: 217-33.
92. Allen C, Halbrook J, Nickoloff JA. Interactive competition between homologous recombination and non-homologous end joining. Mol Cancer Res 2003; 1: 913-20.
93. Sado K, Ayusawa D, Enomoto A, et al. Identification of a mutated DNA ligase IV gene in the X-ray-hypersensitive mutant SX10 of mouse FM3A cells. J Biol Chem 2001; 276: 9742-8.
94. So S, Adachi N, Lieber MR, Koyama H. Genetic interactions between BLM and DNA ligase IV in human cells. J Biol Chem 2004; 279: 55433-42.
95. Modrich P. Mechanisms and biological effects of mismatch repair. Annu Rev Genet 1991; 25: 229-53.
96. Kunkel TA, Erie DA. DNA mismatch repair. Annu Rev Biochem 2005; 74: 681-710.
97. Kolodner RD, Alani E. Mismatch repair and cancer susceptibility. Curr Opin Biotechnol 1994; 5: 585-94.
98. Ghimenti C, Tannergard P, Wahlberg S, et al. Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumors. Br J Cancer 1999; 80: 11-6.
99. O'Brien V, Brown R. Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis 2006; 27: 682-92.
100. Fink D, Nebel S, Aebi S, et al. Expression of the DNA mismatch proteins hMLH1 and hPMS2 in normal human tissues. Br J Cancer 1997; 76: 890-3.
101. Friedrich M, Villena-Heinsen C, Meyberg R, et al. Immunohistochemical analysis of DNA "mismatch-repair" enzyme human mut-S-homolog-2 in ovarian carcinomas. Histochem J 1999; 31: 717-22.
102. Acharya S, Wilson T, Gradia S, et al. hMSH2 forms specific mispairs-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci USA 1996; 93: 13629-34.
103. Wu J, Zhu BB, Yu J, et al. In vitro and in vivo modulations of benzo[c]phenanthrene-DNA adducts by DNA mismatch repair system. Nucleic Acids Res 2003; 31: 6428-34.
104. Bevilacqua RA, Simpson AJ. Methylation of the promoter but no hMLH1 mutations in sporadic gastric carcinomas with high-level microsatellite instability. Int J Cancer 2000; 87: 200-3.
105. Fink D, Zheng H, Nebel S, et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997; 57: 1841-5.
106. Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 1999; 59: 159-64.
107. Fleisher AS, Esteller M, Wang S, et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 1999; 59: 1090-5.
108. Aebi S, Fink D, Gordon R, et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 1997; 3: 1763-7.
109. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56: 3087-90.
110. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 1999; 18: 2335-41.
111. Singhal RK, Prasad R, Wilson SH. DNA polymerase β conducts the gap-filling step in uracil-initiated base excision repair in a bovine testis nuclear extract. J Biol Chem 1995; 270: 949-57.
112. Duncan T, Trewick SC, Koivisto P, Bates PA, Lindahl T, Sedgwick B. Reversal of DNA alkylation damage by two human dioxygenase. Proc Natl Acad Sci USA 2002; 99: 16660-5.
113. Mishina Y, Duquid EM, He C. Direct reversal of DNA alkylation damage. Chem Rev 2006; 106: 215-32.
114. Moore MH, Gulbis JM, Dodson EJ, Demple B, Moody PCE. Crystal structure of a suicidal DNA repair protein: the Ada O6-methylguanine-DNA methyltransferase from E. coli. EMBO J 1994; 13: 1495-501.
115. Ragg S, Xu-Welliver M, Bailey J, et al. Direct REVERSAL of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res 2000; 60: 5187-95.
116. Fang MZ, Jin Z, Wang Y. Promoter hypermethylation and inactivation of O(6)-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines. Int J Oncol 2005; 26: 615-22.
117. Wu M, Kelley MR, Hansen WK, Martin WJ. Reduction of BCNU toxicity to lung cells by high-level expression of O6-methyl-guanine-DNA methyltransferase. Am J Physiol Lung Cell Mol Physiol 2001; 280: L755-L61.
118. Cai S, Xu Y, Cooper RJ, et al. Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents. Cancer Res 2005; 65: 3319-27.
119. Baumann S, Keller G, Pühringer F, et al. The prognostic impact of O6-methylguanine-DNA methyltransferase (MGMT) promotor hypermethylation in esophageal adenocarcinoma. Int J Cancer 2006; 119: 264-8.
120. Yu JJ, Mu CJ, Lee KB, et al. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res Genomics 1997; 382: 13-20.
121. Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/ oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91: 344-54.
122. Viguier J, Boige V, Miquel C, et al. ERCC1 odon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/ 5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005; 11: 6212-7.
123. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10: 4939-43.
124. Ryu J-S, Hong Y-C, Han H-S, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004; 44: 311-6.
125. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004; 15: 1194-203.
126. Milner BJ, Allan LA, Eccles DM, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53: 2128-32.
127. Carr AM. piecing together the p53 puzzle. Science 2000; 287: 1765-6.
128. Nag A, Germaniuk-Kurowska A, Dimri M, et al. An essential role of human Ada3 in p53 acetylation. J Biol Chem 2007; 282: 8812-20.
129. Yamamoto H, Ozaki T, Nakanishi M, et al. Oxidative stress induces p53-dependent apoptosis in hepatoblastoma cell through its nuclear translocation. Genes Cells 2007; 12: 461-71.
130. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005; 18(Suppl 2): 19-32.
131. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20: 2310-8.
132. Koul A, Malander S, Loman N, et al. BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features. Int J Gynecol Cancer 2000; 10: 289-95.
133. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008; 68: 2581-6.
134. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451: 1116-20.
135. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1994; 54: 3500-5.
136. Cummings M, Higginbottom K, McGurk CJ, et al. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: Role of ERCC1 in homologous recombination repair. Biochem Pharmacol 2006; 72: 166-75.
137. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-9.
138. Watanabe Y, Ueda H, Etoh T, et al. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer. Anticancer Res 2007; 27: 1449-52.
139. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 2004; 10: 4420-6.
140. Mackay HJ, Cameron D, Rahilly M, et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 2000; 18: 87-93.
141. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60: 6039-44.
142. Issa JPJ. DNA methylation as a therapeutic target in cancer. Clin Cancer Res 2007; 13: 1634-7.
143. Lyko F, Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 2005; 97: 1498-506.
144. Dobosy JR, Selker EU. Emerging connections between DNA methylation and histone. Cell Mol Life Sci 2001; 58: 721-7.
145. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007; 109: 2781-90.
146. Barlési F, Giaccone G, Gallegos-Ruiz MI, et al. Global histone modifications predict prognosis of resected non-small-cell lung cancer. J Clin Oncol 2007; 25: 4358-64.
147. Okitsu CY, Hsieh CL. DNA methylation dictates histone H3K4 methylation. Mol Cell Biol 2007; 27: 2746-57.
148. Gilbert J, Gore SD, Herman JG, Carducci MA. The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 2004; 10: 4589-96.
149. Matzke M, Matzke AJ, Kooter JM. RNA: Guiding gene silencing. Science 2001; 293: 1080-3.
150. Hübscher U, Maga G, Spadari S. Eukaryotic DNA polymerases. Annu Rev Biochem 2002; 71: 133-63.
151. Goodman MF. Error-prone repair DNA polymerases in prokaryotes and eukaryotes. Annu Rev Biochem 2002; 71: 17-50.
152. Pursell ZF, Isoz I, Lundström EB, Johansson E, Kunkel TA. Yeast DNA polymerase ε participates in leading-strand DNA replication. Science 2007; 317: 127-30.
153. Hoffmann J-S, Pillaire M-J, Maga G, et al. DNA polymerase β bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene. Proc Natl Acad Sci USA 1995; 92: 5356-60.
154. Albertella MR, Green CM, Lehmann AR, O'Connor MJ. A role for polymerase η in the cellular tolerance to cisplatin-induced damage. Cancer Res 2005; 65: 9799-806.
155. Canitrot Y, Cazaux C, Frechet M, et al. Overexpression of DNA polymerase β in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc Natl Acad Sci USA 1998; 95: 12586-90.
156. Bergoglio V, Canitrot Y, Hogarth L, et al. Enhanced expression and activity of DNA polymerase β in human ovarian tumour cells: impact on sensitivity towards antitumour agents. Oncogene 2001; 20: 6181-7.
157. Bassett E, Vaisman A, Tropea KA, et al. Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases and β and ε DNA Repair 2002; 1: 1003-16.
158. Vaisman A, Chaney SE. The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin adducts by human DNA polymerase β. J Biol Chem 2000; 275: 13017-25.
159. Alt A, Lammens K, Chiocchini C, et al. Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase eta. Science 2007; 318: 967-70.
160. Albertella MR, Green CM, Lehmann AR, O'Connor MJ. A role for polymerase η in the cellular tolerance to cisplatin-induced damage. Cancer Res 2005; 65: 9799-806.
161. Berger NA, Kurohara KK, Petzold SJ, Sikorski GW. Aphidicolin inhibits eukaryotic DNA replication and repair - implications for involvement of DNA polymerase α in both processes. Biochem Biophys Res Commun 1979; 89: 218-25.
162. Chao CC-K. Enhanced excision repair of DNA damage due to cis-diamminedichloroplatinum II) in resistant cervix carcinoma HeLa cells. Eur J Pharmacol 1994; 268: 347-55.
163. Pohlmann P, DiLeone LP, Cancella AI, et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 2002; 25: 496-501.
164. Appleton K, Mackay HJ, Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007; 25: 4603-9.
165. Plimack ER, Stewart DJ, Issa JPJ. Combining epigenetic and cytotoxic therapy in the treatment of solid tumors. J Clin Oncol 2007; 25: 4519-21.
166. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-54.
167. Holowiecki J, S Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia 2004; 18: 989-97.
168. Issa J, Kantarjian HM, Saba HI. Cytogenetic responses to the hypomethylating agent, decitabine (DAC), in a phase III trial of DAC vs supportive care (SC) in patients (pts) with myelodysplastic syndromes (MDS). J Clin Oncol 2006; 24: 6501.
169. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429-40.
170. Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell 2007; 11: 103-5.
171. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104: 2807-16.
172. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
173. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 2005; 5: 388-93.
174. Vogel KJ, Atchley DP, Erlichman J, et al. BRCA1 and BRCA2 genetic testing in hispanic patients: Mutation prevalence and evaluation of the BRCAPRO risk assessment model. J Clin Oncol 2007; 25: 4635-41.
175. Steligo K. Targeted therapy: specific treatments for hereditary cancer. Facing Our Risk of Cancer Empowered 2005; 1: 2.